# Insulet Corporation

> Insulet Corporation develops and manufactures Omnipod wearable insulin delivery systems. Its disposable, tubeless Pods serve people with insulin-requiring diabetes; Omnipod 5 pairs insulin delivery with compatible glucose sensors and an on-Pod algorithm. Insulet reported $2.7081 billion in 2025 revenue and more than 600,000 estimated active Omnipod users worldwide at year-end.

- **Founded:** 2000
- **Headquarters:** Acton, United States
- **Founders:** John Brooks III (Co-founder)
- **Products:** Omnipod Insulin Management System, Omnipod DASH, Omnipod 5, Omnipod GO, Non-insulin drug-delivery Pods
- **Notable:** Omnipod 5 U.S. launch in 2022., FDA expanded SmartAdjust’s indication to adults with type 2 diabetes in August 2024., More than 600,000 estimated active Omnipod users at year-end 2025.

## Products & services

- **Omnipod Insulin Management System** — Disposable, wearable insulin delivery Pod platform; the original U.S. commercial launch was in 2005.
- **Omnipod DASH** — Bluetooth-enabled tubeless Pods operated by a touchscreen Personal Diabetes Manager; U.S. FDA clearance in June 2018. Does not provide Omnipod 5 automated insulin adjustment.
- **Omnipod 5** — Automated insulin delivery system with an on-Pod algorithm and compatible CGM integration. U.S. launch in 2022; U.S. type 2 adult indication added in 2024.
- **Omnipod GO** — Basal-only Pod that entered a commercial pilot; Insulet subsequently decided against commercialization and prioritized Omnipod 5 for type 2 diabetes.
- **Non-insulin drug-delivery Pods** — Pod technology supplied for applications including Amgen’s Neulasta Onpro kit.

## Achievements

- Omnipod 5 U.S. launch in 2022.
- FDA expanded SmartAdjust’s indication to adults with type 2 diabetes in August 2024.
- More than 600,000 estimated active Omnipod users at year-end 2025.
- 2025 revenue rose 30.7% to $2.7081 billion.
- Omnipod sold in 26 countries by August 2026.

## Latest updates

- **2026-08** — Reported Q2 revenue of $801.7 million, up 23.5%; reduced full-year U.S. Omnipod constant-currency growth guidance to 17%-19% from 20%-22%. Spain became the 26th Omnipod country and 20th Omnipod 5 country.
- **2026-05** — Announced a separate voluntary correction for specified Omnipod 5, DASH and Eros Pod lots because cannula tears could cause insulin under-delivery; approximately seven million Pods were in scope.
- **2026-02** — Reported 2025 revenue of $2.7081 billion and more than 600,000 estimated active Omnipod users at December 31, 2025.

## Links

- Website: https://www.insulet.com/
- LinkedIn: https://www.linkedin.com/company/insulet-corporation/
- Twitter/X: https://x.com/myomnipod
- YouTube: https://www.youtube.com/channel/UCgwZ9hRegg6DZXqY4ji60vQ
- Instagram: https://www.instagram.com/omnipod/
- Facebook: https://www.facebook.com/myomnipod/

---

Profile page: https://yespress.io/insulet-corporation
Published by YesPress — https://yespress.io
Last updated: 2026-10-24